https://scholars.lib.ntu.edu.tw/handle/123456789/496063
標題: | Sitagliptin may reduce prostate cancer risk in male patients with type 2 diabetes | 作者: | CHIN-HSIAO TSENG | 關鍵字: | Incretin; National Health Insurance; Prostate cancer; Sitagliptin; Taiwan | 公開日期: | 2017 | 出版社: | Impact Journals LLC | 卷: | 8 | 期: | 12 | 起(迄)頁: | 19057-19064 | 來源出版物: | Oncotarget | 摘要: | This retrospective cohort study evaluated the risk of prostate cancer associated with sitagliptin use in Taiwanese male patients with type 2 diabetes mellitus by using the reimbursement databases of the National Health Insurance. Male patients with newly diagnosed type 2 diabetes mellitus at an age ?25 years between 1999 and 2010 were recruited. A total of 37,924 ever users of sitagliptin and 426,276 never users were followed until December 31, 2011. The treatment effect of sitagliptin (for ever versus never users, and for tertiles of cumulative duration of therapy) was estimated by Cox regression incorporated with the inverse probability of treatment weighting using propensity score. Analyses were also conducted in a 1:1 matched pair cohort based on 8 digits of propensity score. Results showed that during follow-up, 84 ever users and 2,549 never users were diagnosed of prostate cancer, representing an incidence of 140.74 and 240.17 per 100,000 person-years, respectively. The hazard ratio (95% confidence intervals) for ever users versus never users was 0.613 (0.493- 0.763). The respective hazard ratio for the first, second, and third tertile of cumulative duration of sitagliptin use < 5.9, 5.9-12.7 and > 12.7 months was 0.853 (0.601-1.210), 0.840 (0.598-1.179) and 0.304 (0.191-0.483), respectively; and was 0.856 (0.603- 1.214), 0.695 (0.475-1.016) and 0.410 (0.277-0.608) for cumulative dose < 15,000, 15,000-33,600 and > 33,600 mg, respectively. Findings were supported by analyses in the matched cohort. In conclusion, sitagliptin significantly reduces the risk of prostate cancer, especially when the cumulative duration is > 12.7 months or the cumulative dose > 33,600 mg. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85015801009&doi=10.18632%2foncotarget.12137&partnerID=40&md5=0b7ed8f85098a8836ffbcf2005667421 https://scholars.lib.ntu.edu.tw/handle/123456789/496063 |
ISSN: | 1949-2553 | DOI: | 10.18632/oncotarget.12137 | SDG/關鍵字: | sitagliptin; antidiabetic agent; sitagliptin; adult; Article; cancer incidence; cancer risk; cohort analysis; controlled study; follow up; hazard ratio; human; major clinical study; male; non insulin dependent diabetes mellitus; probability; propensity score; prostate cancer; retrospective study; risk reduction; Taiwanese; treatment duration; aged; Diabetes Mellitus, Type 2; incidence; middle aged; proportional hazards model; Prostatic Neoplasms; Taiwan; Adult; Aged; Cohort Studies; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Incidence; Male; Middle Aged; Propensity Score; Proportional Hazards Models; Prostatic Neoplasms; Retrospective Studies; Sitagliptin Phosphate; Taiwan |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。